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Objectives/Hypothesis: To develop and validate a simple prognostic tool that would help predict larynx preservation
outcome.
Study Design: A retrospective review of 3 prospective studies.
Methods: We reviewed consecutive chemotherapy/radiation protocols for patients (n ¼ 170) with advanced, resectable,
squamous cell, larynx, or pharynx cancer treated at Memorial Sloan-Kettering Cancer Center from 1988 to 1995 with larynx
preservation intent. The outcome was successful larynx preservation. Model validation used data from U. S. Department of
Veterans Affairs larynx preservation study.
Results: The developed model added one point for each poor prognostic covariate present (show in parentheses) and
was given the acronym TALK: T stage (T4), albumin (<4 g/dL), maximum alcohol/liquor use (6 drinks/day or heavy drink-
ing), and Karnofsky performance status (<80%). The 3-year larynx preservation rates by TALK score were 65% (0), 41%
(1–2), and 6% (3–4), P < .0001; on validation, the TALK 3–4 group was particularly well demarcated.
Conclusions: The TALK score is an easily applied and valid tool that should assist treatment selection.
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INTRODUCTION
Most advanced cancers of the larynx and surround-
ing structures require total laryngectomy if managed
with primary surgery. This operation is among those
most feared by patients.1 Both voice alteration and
related communication challenges, as well as the pres-
ence of a stoma may adversely affect quality of life.2,3
Voice rehabilitation strategies exist, but many patients
feel totally or partly dissatisfied with the options and
continue to feel restricted in their daily lives.4 Accord-
ingly, the development of treatment programs intended
to preserve laryngeal function without compromising
survival is an important priority within head and neck
oncology and of great interest to patients.
Historically, conservation surgery5,6 and radiation7
as a single modality had been the principal larynx pres-
ervation options. In the last 15 years, integrated
chemotherapy/radiotherapy has established itself as a
broadly applicable larynx preservation strategy.
Randomized trials have shown that such an approach
offers voice preservation and improved quality of life
without compromise in survival.8–10
When successful organ preservation is achieved,
chemotherapy/radiation is generally viewed as having
been the appropriate treatment choice for the patient;
unfortunately, in some patients the strategy will fail. In
this setting, a patient would have experienced the potential
toxicities of chemotherapy (e.g., neuropathy, hearing loss)
and definitive-dose radiation therapy (e.g., increased risk
of severe mucositis, feeding tube) and the potential added
morbidity associated with surgery after those treatments
without any apparent benefit and many added costs. Argu-
ably, such patients would have been better served by
proceeding directly to primary total laryngectomy. Under-
standably, knowing whether a given patient has a higher
or lower likelihood of success with chemotherapy/radiation
therapy would be useful to both physicians and patients.
There is currently no validated methodology avail-
able to help separate better from poorer risk patients
before the initiation of larynx preservation therapy.
Therefore, treatment choice is often subjective and may
use widely varying, difficult-to-reproduce criteria. Our
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objective was to create a simple prognostic tool using
readily available clinical data that would help predict
successful and, perhaps more importantly, unsuccessful
larynx preservation outcome to facilitate treatment deci-
sion making in this setting.
MATERIALS AND METHODS
Patients
From 1988 to 1995, 173 patients with histologically con-
firmed squamous cell carcinoma of the larynx, hypopharynx, or
oropharynx were treated on one of two consecutive, institutional
review board–approved protocols at Memorial Sloan-Kettering
Cancer Center with the primary intent of preserving the larynx.
Seventy patients participated in the first protocol (1988–1990),
and 103 patients participated in the second protocol (1991–1995).
Three patients were found to be ineligible (2 with nonsquamous
cell histology; 1 with M1 disease before initial treatment) and were
excluded. Therefore, a total of 170 patients were included in this
study. All histologic material was reviewed by the department of
pathology at Memorial Hospital. Entry criteria were similar
among the studies and have been previously described.11–13 All
patients gave informed consent after the studies were approved by
the local human investigations committee.
Treatment
The details of treatment have been previously discussed11–13
and are summarized in Table I and II. In both studies, three
cycles of induction cisplatin-based combination chemotherapy
were planned with appropriate supportive measures.14 The de-
cision whether to proceed to radiation-based treatment or
primary surgical management depended on the extent of
response to chemotherapy. In general, patients with a major
response at the primary site and no progression in the neck pro-
ceeded to radiation-based treatment; for lesser response
categories and progression, surgical intervention was recom-
mended. The patients on the first protocol received conventional
external-beam radiation that was delivered in 1.8- to 2-Gy frac-
tions to a planned total dose of 66 to 70 Gy to the primary site
and other sites of gross disease. The patients on the second pro-
tocol received delayed accelerated external-beam radiation
therapy that was delivered in 1.8-Gy daily fractions during
weeks 1 to 4, followed by twice-daily fractions (1.8 Gy in the
morning and 1.6 Gy in the afternoon) during weeks 5 to 6, for a
total planned dose of 70 Gy, with planned concurrent cisplatin
100 mg/m2 administered intravenously on days 1 and 22. On
both studies, selected patients with base of tongue cancer
received a brachytherapy15 boost, and surgery was pursued for
suspected disease persistence or relapse.
Larynx Preservation Outcome
Prospective functional data were not available for these
patients. As a surrogate measure, successful larynx preserva-
tion outcome for this study was defined as local control without
any surgery (except biopsy) to the primary site and without a
permanent tracheostomy or gastrostomy. Such an endpoint has
been successfully used previously.9 Overall survival was not
included as part of this outcome.
Prognostic Variables
T stage, N stage, and overall TNM stage (by clinical exam
alone and with the use of imaging studies to potentially address
stage migration concerns16,17) as well as age, sex, race, primary site,
and Karnofsky performance status had all been collected prospec-
tively. After a comprehensive review of the literature, our data set
was expanded to include other potential pretreatment prognostic
factors, which were collected retrospectively from patient charts.
These pretreatment factors included weight loss,18 symptoms,19–22
comorbidity23 (Charlson comorbidity index24), performance status,25
alcohol use,18,20 cigarette use,26–28 albumin,18 alanine aminotrans-
ferase,29 hemoglobin,29 platelets,30 mean corpuscular volume, lactic
acid dehydrogenase,31 serum albumin,32 and pretreatment trache-
ostomy21,33 and gastrostomy status. All variables were dichotomized
before any modeling applying either cutoff points used in the medi-
cal literature or based on the frequency distribution in the dataset.
Validation Dataset
The U.S. Department of Veterans Affairs (VA) Laryngeal
Study Group performed a prospective randomized study in
patients with stage III or IV larynx cancer.8,33 The protocol and
informed consent procedures were approved by the institutional
review boards at all participating institutions. A total of 332
patients were randomized to receive either standard treatment
(surgery and postoperative radiation therapy) or investigational
treatment (larynx preservation with sequential standard cispla-
tin/5-fluorouracil chemotherapy followed by radiation therapy,
with primary site surgery reserved for disease persistence or
salvage). The full details of treatment plan and outcome have
been previously described.8,34 Data from the 166 subjects who
were randomized to the investigational treatment were used as
the validation dataset.
TABLE I.
Induction Chemotherapy Regimens.
Drugs Dosage Days
Protocol 1988–1990 (n ¼ 70)
Cisplatin 100 mg/m2 IV 1, 29, 57
5-fluorouracil 1,000 mg/m2 CIV 1–5, 29–33, 57–61
Protocol 1991–1995 (n ¼ 103)
Cisplatin (n ¼ 22) 100 mg/m2 IV 1, 22, 43
5-fluorouracil
(n ¼ 22)
800 mg/m2 CIV 1–5, 22–26, 43–47
Leucovorin calcium
(n ¼ 22)
100 mg PO
every 4 hr
1–5, 22–26, 43–47
Cisplatin (n ¼ 81) 100 mg/m2 IV 1, 22, 43
5-fluorouracil
(n ¼ 81)
1,000 mg/m2 CIV 1–5, 22–26, 43–47
IV ¼ intravenous; CIV ¼ continuous intravenous; PO ¼ orally.
TABLE II.
Radiation Therapy Regimens.
Radiation Therapy Cisplatin
Target total dose Fractionation Dosage Days
Protocol 1988–1990 (n ¼ 70)
6,600–7,000 cGy 1.8 Gy/d, wk 1–6 None
Protocol 1991–1995 (n ¼ 103)
7,000 cGy 1.8 Gy/d, wk 1–4 100 mg/m2 IV 1, 22
1.8 Gy/AM, wk 5–6
1.6 Gy/PM, wk 5–6
IV ¼ intravenous.
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Statistics
Larynx preservation times were calculated from the start
of treatment and assigned a value of 0 if local control was never
achieved. Univariate analyses of potential prognostic covariates
were done using the Kaplan-Meier method. Variables with P <
.10 by the log-rank test were included in the multivariate anal-
ysis. Multivariate analysis used Cox’s proportional-hazards
model,35 doing the regression in a forward stepwise manner
with a threshold significant value of .10. P values of .10 were
used in the early phases of the modeling so that potentially predic-
tive factors with borderline P values were not immediately excluded
from the analysis; however, only variables with P < .05 after multi-
variate analysis were included in the final model. Because previous
data suggested that patients in the second protocol (1991–1995) had
better outcomes than those in the first protocol (1988–1990),36 all of
the univariate and multivariate analyses were stratified by the pro-
tocol in which the patient had participated. The candidate variables
for the prognostic tool were derived from the results of the multivar-
iate analysis (2-sided P values < .05). Discrimination was evaluated
using the concordance index.37,38 A concordance index of 1 indicates
that a model performs perfectly in predicting success or failure in
an individual subject.
Median follow-up for both datasets was computed using
the inverse Kaplan-Meier method.39 Median as well as actuarial
larynx preservation and survival times were reported. For sub-
group comparisons of larynx preservation rates, Kaplan-Meier
curves were also presented.
RESULTS
Memorial Sloan-Kettering Cancer Center
Development Dataset
Patient characteristics. The baseline characteris-
tics for those 170 evaluable patients are listed in Table III.
The median age was 59 years (range, 25–84), and me-
dian Karnofsky performance status was 80 (range, 60–
90). The majority of primary sites were of the larynx
(56%); 45% had N2 disease or greater, and 32% had T4
disease. Fifteen percent of the subjects had significant
comorbidity as per the Charlson comorbidity criteria.24
A larger proportion were either current/former consum-
ers of tobacco (93%) or alcohol (68%).
Outcomes. The median follow-up of the patients
was 82.5 months (range, 0.4–141.5 months). Fifteen (9%)
were censored before 3 years; 28 (17%) before 5 years.
The median overall survival and time to larynx preser-
vation failure were 54.5 months and 15 months,
respectively. The 3-year overall survival rate was 59%.
The 3-year larynx preservation rate was 44%.
Univariate analyses. After analyzing the break-
down of each variable and considering clinically relevant
values, each factor was dichotomized as listed in Table
IV. Each of the potential prognostic covariates listed in
Table IV underwent univariate analysis for larynx pres-
ervation outcome. T stage, alcohol use, Karnofsky
performance status, lactate dehydrogenase, albumin,
platelets, weight loss, pretreatment tracheostomy, and
overall stage (P < .05 by log-rank test) as well as the
symptom of dyspnea (P < .1) were all significant covari-
ates. Cigarette use, either as a dichotomous variable or
a continuous variable by pack years (data not shown),
was not a significant predictor. The times of last ciga-
rette or alcohol used were also examined both as a
continuous variable as well as a dichotomous variable
(using 1 month and 1 year as break points), and neither
was found to significantly predict successful larynx pres-
ervation in our data set.
Multivariate analysis. Two variables that were
significant on univariate analysis were excluded from
the multivariate analysis. Lactate dehydrogenase was
excluded because less than 10% of the subjects had an
abnormally high value pretreatment. Weight loss was
excluded owing to concerns about the accuracy of the
data using only chart review, particularly the time over
which weight loss occurred. All of the other eight varia-
bles that were found to predict successful larynx
preservation (P < .10) were entered in the Cox’s propor-
tional-hazards model. Because of missing data, three
subjects (all with larynx cancer as the primary) were
excluded from all subsequent analyses. As noted in
Table V, four of the variables remained independently
significant (P < .05): T stage (T3 vs. T4), serum albu-
min level (<4 g/dL vs. 4 g/dL), Karnofsky performance
status (<80% vs. 80%), alcohol/liquor use (described as
minor or no alcohol use in the past or <6 cans of beer, or
the equivalent alcohol, per day during maximum alcohol
use vs. described as major alcohol use in the past or 6
cans of beer, or the equivalent alcohol, per day during
maximum alcohol use). Pretreatment albumin levels had
the highest risk ratio (2.55); the risk ratios are similar
among the other three variables (1.60-1.77).
TALK score. The risk of unsuccessful larynx pres-
ervation was characterized by summing the number of
risk factors present at time of diagnosis (Table V). Even
though the risk ratio for pretreatment albumin was
higher than the other variables, this approach was taken
TABLE III.
Demographic Characteristics.
No. of Patients %
No. 173 —
No. analyzed 170 —
Age, median (range), yr 59 (25–84) —
KPS, median (range) 80 (60–90) —
Male/female 123/47 72/28
Pretreatment tracheostomy 31 18
Weight loss 10% 28 16
Charlson comorbidity >3* 25 15
Site
Larynx 96 56
Hypopharynx 47 28
Oropharynx 27 16
Stage
T2/T3/T4 21/73/76 12/43/45
N0/N1/N2/N3 57/30/77/6 34/18/45/4
Stage II/III/IV 6/47/117 11/34/55
Current/former smokers 158 93
Current/former alcohol users 53 68
*Because of the diagnosis of cancer, all patients had a minimum
score of 2.
KPS ¼ Karnofsky performance status.
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because there exists overlap of the 95% confidence inter-
vals of the risk ratios. For example, a patient who had a
T4 tumor (a risk factor), serum albumin level of 3 g/dL (a
risk factor), a Karnofsky score of 90% (NOT a risk factor),
and never drank alcohol (NOT a risk factor) would have a
score of 2 (due to 2 risk factors). Kaplan-Meier curves for
each possible TALK score with successful larynx preserva-
tion as the outcome are shown in Figure 1. The curves for
TALK scores of 1 and 2 were close by visual inspection, so
they were combined to represent an intermediate risk for
successful larynx preservation. Similarly, the curves for
TALK scores of 3 and 4 were close by visual inspection
and were therefore combined. Thus, a patient was defined
as at good risk if no risk factors were present, intermedi-
ate risk if one or two risk factors were present, and poor
risk if three or four factors were present.
Furthermore, it was noted that the first letter of
each risk factor (T stage, albumin, alcohol/liquor use, Kar-
nofsky performance status) made up the acronym TALK.
The prognostic model was renamed the TALK score to
facilitate the ability to remember the risk factors.
Figure 2A and Table VI summarize larynx preser-
vation rates over time for each prognostic group. The
3-year larynx preservation rates for the good (TALK
score ¼ 0), intermediate (TALK score ¼ 1 or 2), and poor
(TALK score ¼ 3 or 4) risk groups were 65%, 41%, and
6%, respectively. The median time to larynx preservation
failure (and the 95% confidence intervals) for the good-,
intermediate-, and poor-risk groups were not reached
(117 months: not reached), 14 months (10–37), and 0
months (0–2), respectively. These differences were signifi-
cant (P < .0001 by log-rank test). All but one patient’s
cancer in the poor-risk group had larynx preservation
failure by 3 years. In the studied population, the majority
of the patients (57%) fell into the intermediate-risk group;
18 patients (11%) were in the poor-risk group.
In the developmental dataset, the concordance
index of the TALK score was 0.65.
TALK score for larynx cancer only. Because only
laryngeal cancer patients were part of the validation set,
the TALK score model was also applied only to the lar-
ynx cancer patients in the Memorial Hospital dataset.
TABLE IV.
Univariate Analysis of Pretreatment Factors.
Pretreatment Factors Dichotomization P < .10
Age, yr <60 vs. 60 *
Sex Male vs. female *
Race Caucasian vs. non-Caucasian *
Primary site Larynx vs. hypopharynx or oropharynx *
T stage <T4 vs. T4 <.001
N stage <N2 vs. N2 *
Overall stage II or III vs. IV .037
Karnofsky performance status, % <80 vs. 80 <.001
Tracheostomy Yes vs. no .004
PEG Yes vs. no *
Laboratory serum tests
Lactic acid dehydrogenase Normal vs. higher than ULN .027
Albumin, g/dL <4 vs. 4 <.001
Mean corpuscular volume, fl <100 vs. 100 *
Alanine aminotransferase Normal vs. higher than ULN *
Hemoglobin, g/dL <10 vs. 10 *
Platelets Normal vs. higher than ULN .002
Cigarette use Yes vs. no *
>40 pack years <40 vs. 40 *
Alcohol use Described as minor or no alcohol use in the past or <6 cans of
beer/d, or the equivalent, during maximum alcohol use vs. described
as major alcohol use in the past or 6 cans of beer/d, or the
equivalent, during maximum alcohol use
.032
Weight loss, % <10 vs. 10 .002
Symptoms
Dysphagia Yes vs. no *
Otalgia Yes vs. no *
Neck mass Yes vs. no *
Dyspnea Yes vs. no .081
Sore throat Yes vs. no *
Charlson comorbidity index <4 vs. 4 *
*P > .10.
PEG ¼ percutaneous endoscopic gastrostomy; ULN ¼ upper limits of normal.
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Overall, there were 93 evaluable subjects with larynx
cancer. The 3-year larynx preservation rates (Table VI)
for the good- (35 subjects), intermediate- (50 subjects),
and poor-risk (8 subjects) groups were 68%, 41%, and
13%, respectively. The median time to larynx preserva-
tion failure (and the 95% confidence intervals) for the
good-, intermediate-, and poor-risk groups were not
reached (lower interval not reached-upper interval not
reached), 14 months (9–73), and 0 months (0–8), respec-
tively. These differences were significant (P < .0001 by
log-rank test). The larynx preservation Kaplan-Meier
curves for the patients with larynx cancer only are illus-
trated in Figure 2B.
The concordance index of the TALK score in the lar-
ynx cancer subgroup was also 0.65.
Department of Veterans Affairs Laryngeal
Cancer Study - Validation Dataset
Patient characteristics. There were a total of 166
evaluable patients in this population. All subjects in the VA
Laryngeal Cancer Study had larynx cancer as the primary
site. Of the subjects in this dataset, 26% had T4 disease;
28% had N2 or N3 disease; and 44% had stage IV disease.
Overall outcomes. The median follow-up was 52
months. The actuarial 3-year overall survival rate was
52%. The 3-year larynx preservation rate was 44%. The
median time to larynx preservation failure was 21
months. Compared to the Memorial Hospital data, there
were more patients censored early: 25 (15%) before 3
years and 49 (30%) before 5 years.
TALK score for the VA dataset. When TALK was
applied to the VA Laryngeal Cancer Study dataset, 27
subjects (16%) were in the good-risk group, 109 (66%)
were in the intermediate-risk group, and 30 (18%) were
in the poor-risk group (Table VI). The 3-year larynx
preservation rates were 54%, 47%, and 25% for the
good-, intermediate-, and poor-risk groups, respectively.
The median time to larynx preservation failure (and the
95% confidence intervals) for the good-, intermediate-,
TABLE V.
Hazard-Cox Forward Stepwise Regression, TALK Score Model.
Variables Condition Pr > v2 Hazard Ratio 95% Confidence Interval TALK Score
T stage* T4 .008 1.76 1.16-2.68 1
Albumin <4 g/dL .001 2.55 1.44-4.51 1
Alcohol use (or liquor use) Major alcohol use
or >6 cans of beer/d
.023 1.60 1.07-2.41 1
Karnofsky performance status <80% .025 1.77 1.08-2.90 1
*Staging with the use of radiologic evaluation.
TALK ¼ T stage, albumin, alcohol/liquor use, Karnofsky performance status.
Fig. 1. Kaplan-Meier curves describing larynx preservation rates
for each TALK score value. TALK ¼ T stage, albumin, alcohol/liq-
uor use, Karnofsky performance status.
Fig. 2. (A) TALK score model; Memorial Sloan-Kettering Cancer
Center data set—all patients. (B) TALK score model; Memorial
Sloan-Kettering Cancer Center data set—larynx cancer patients
only. TALK ¼ T stage, albumin, alcohol/liquor use, Karnofsky per-
formance status.
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and poor-risk groups were 47 months (11; upper interval
not reached), 24 months (10; upper interval not reached),
and 7 months (2–13), respectively. These differences were
significant (P < .01 by log-rank test). It should be noted in
the actuarial larynx preservation curves provided in Fig-
ure 3 that the demarcation at 3 years in the larynx
preservation between the good (TALK score ¼ 0) and in-
termediate (TALK score ¼ 1 or 2) groups did not persist
beyond 48 months. Furthermore, seven of the 30 patients
in the poor-risk group were censored before the 3-year
mark (only 3 patients were censored after 3 years).
In the validation dataset, the concordance index of
the TALK score was 0.57.
DISCUSSION
The goal of this project was to develop and validate
a simple tool that supplies health-care providers and
patients with added prognostic data to assist decision
making in the larynx preservation setting. The result of
our analysis is the TALK score, which demarcated a sig-
nificant prognostic gradient in larynx preservation
outcome in both our (development) and the VA Laryn-
geal Cancer Study (validation) datasets. The inclusion of
the validation step distinguishes our report from other
prognostic analyses intended to assist prediction of larynx
preservation outcome available in the literature. Numer-
ous clinical factors were analyzed as potential candidates
for the prognostic model. Many of these factors, such as
comorbidity, symptoms, and alcohol/smoking history, are
not routinely collected during the analyses of the manage-
ment options in patients with cancer. The TALK score
consists of T stage, serum albumin level, alcohol/liquor
use, and Karnofsky performance status.
Not surprisingly, the development dataset demon-
strated a large gradient between groups. In the
validation dataset from the VA Laryngeal Cancer Study,
the TALK score’s ability to select a poor-risk group, rep-
resenting nearly 20% of patients in the study, is also
well demonstrated. However, a durable separation of
larynx preservation rates between the good- and inter-
mediate-risk groups was not delineated. Potential
explanations to consider include a smaller proportion of
VA Laryngeal Cancer Study patients in the good-risk
group compared to our population (16% vs. 37%) and the
impact of approximately 30% of the VA Laryngeal Can-
cer Study subjects being censored before 5 years of
follow-up compared to 17% in the Memorial Hospital
dataset. Future work will need to identify ways to fur-
ther delineate between these groups. Arguably, however,
the true value of the TALK score is the ability to predict
unsuccessful, not successful, larynx preservation. In gen-
eral, costs and morbidity are higher in subjects who
undergo and fail larynx preservation treatment, as they
are exposed to additional, potentially toxic, treatments
TABLE VI.
TALK Score Groups.
Dataset TALK Score Risk Grouping No.* Median LP Rate, mo 3-Year LP Rate, %
MSKCC (all)
0 Good 53 Not reached 65
1–2 Intermediate 96 14 41
3–4 Poor 18 0 6
Total 167 15 44
MSKCC (larynx only)
0 Good 35 Not reached 68
1–2 Intermediate 50 14 41
3–4 Poor 8 0 13
Total 93 28 49
VA
0 Good 27 47 54
1–2 Intermediate 109 24 47
3–4 Poor 30 7 25
Total 166 21 44
TALK ¼ T stage, albumin, alcohol/liquor use, Karnofsky performance status; LP ¼ larynx preservation; MSKCC ¼ Memorial Sloan-Kettering Cancer Cen-
ter; VA ¼ Department of Veterans Affairs Laryngeal Study Group.
Fig. 3. TALK score model; the Department of Veterans Affairs lar-
ynx preservation study. TALK ¼ T stage, albumin, alcohol/liquor
use, Karnofsky performance status.
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that would have been avoided with upfront surgery and
adjuvant radiation therapy. Because studies have shown
patients to strongly prefer avoiding surgery if possi-
ble,10,40 particularly if survival is not compromised, we
anticipate that the majority of patients would choose a
larynx preservation option if there exists a reasonable
chance of success. Therefore, the clinical impact on deci-
sion-making between the good- and intermediate-risk
groups is likely much smaller than between the interme-
diate- and poor-risk groups. The TALK score’s ability to
identify a poor-risk group is its strength.
The TALK score is simple to use. All variables were
dichotomized to facilitate its application. Also, all of the
variables are routinely collected by physicians before the
initiation of treatment and, for the most part, are inde-
pendent of high technology. The sole exception to this is
the T stage, which was measured with the aid of a com-
puterized axial tomography scan or magnetic resonance
imaging. T stage, based on clinical exam but not imag-
ing, was significant in predicting local control with a
functional larynx after multivariate analysis (data not
shown) but with a lower relative risk ratio. Neverthe-
less, most physicians do get a pretreatment imaging
study of the primary site. The TALK score provides an
objective and valid method to predict the likelihood of
successful larynx preservation and an alternative to
more subjective, likely less reproducible approaches.
There exist several potentially important applica-
tions of the TALK score. First, the TALK score can be
used to compare larynx preservation rates from separate
nonrandomized larynx preservation trials by allowing
investigators to compare the baseline prognostic risks of
patients entered in different studies. Second, it will give
the patient and clinician additional prognostic data to
make an informed decision. However, the health-care
provider should not use this model to make a clinical
decision independent of the patient. Evidence suggests
that health-care providers often gauge patient preferen-
ces or quality of life inaccurately.2,41–43 Third, if a
patient falls into the poor-risk category but truly wishes
to pursue a larynx preservation option, an investiga-
tional, instead of a standard, larynx preservation
approach may be a better treatment choice.
There are certain limitations to this model. The
TALK score was created and validated on protocol data
sets. Patients participating in clinical trials are required
to pass stricter inclusion criteria (see Methods section)
than those receiving noninvestigational therapy. Clinical
factors that may have importance in a less-selected
population may not have been reflected in this clinical
trial setting. An example is comorbidity. Although many
patients with high comorbidity are excluded from clini-
cal trials, this will not be the case for the head and neck
cancer population at large, especially considering the
influence of cigarette smoking44 and alcohol use45 as
risk factors for these diseases.
A limitation to the study is the lack of data pertain-
ing to human papillomavirus (HPV) status. It was not
until after these studies were completed that HPV was
found to be associated with a subset of squamous cell
carcinomas of the head and neck.46–48 More recent work
has shown that HPV-related squamous cell cancers of
the head and neck have a favorable prognosis compared
to HPV-negative tumors.49,50 However, the risk of HPV
in non-oropharynx tumors is very low.49,51 Considering
only 16% of our development dataset consisted of oro-
pharynx tumors, and there were no oropharynx tumors
in our validation dataset, it is unlikely that HPV status
is a confounder in our model, although the model is
most likely relevant only for HPV-negative tumors.
In addition to HPV, other studies have identified
biological markers27,52–56 as well as other clinical character-
istics8,33,56 that may help predict larynx preservation
outcome. Examples include the presence of p53 mutations,
vascular endothelial growth factor levels, and epidermal
growth factor receptor expression. Although the addition of
these factors to the TALK score will be considered in future
models, the TALK score model in its current form represents
a simple and easy to apply model that supplies important in-
formation quickly without the aid of difficult, time-
consuming, and/or expensive investigations.
The concordance index of 0.57 for the TALK score
when applied to the validation dataset indicated that the
model performed better than pure chance in this popula-
tion but was well below an index of 1 associated with a
perfect model. A concordance index in this range is none-
theless consistent with clinical utility. For example, the
Gail model,57 which is widely used to predict breast can-
cer risk, has a reported concordance index of 0.58.58
CONCLUSION
The TALK score represents a beginning, a backbone
for further prognostic model development in this clinical
setting, for which tools to guide management are solely
needed. It is likely most relevant to HPV-negative squa-
mous cell cancers of the head and neck. We anticipate
further refinement in the scale. For example, other stud-
ies have identified biologic markers27,52–56 as well as
other clinical characteristics8,33,56 that may help predict
larynx preservation outcome. The addition of selected
prognostic factors with the intent of creating a better
predictive model while preserving ease of use is being
considered for future investigations.
Acknowledgment
The authors acknowledge the assistance of Michael
Kattan, PhD, for his constructive review of the manu-
script. Many individuals have been prominently involved
in our larynx preservation program over the years, and the
authors would particularly like to acknowledge the contri-
butions of Elliot Strong, MD, Ronald Spiro, MD, and Louis
Harrison,MD, in this regard.
BIBLIOGRAPHY
1. Dropkin MJ, Malgady RG, Scott DW, Oberst MT, Strong EW. Scaling of
disfigurement and dysfunction in postoperative head and neck patients.
Head Neck Surg 1983;6:559–570.
2. Mohide EA, Archibald SD, Tew M, Young JE, Haines T. Postlaryngectomy
quality-of-live dimensions identified by patients and health care profes-
sionals. Am J Surg 1992;164:619–622.
3. DeSanto LW, Olsen KD, Perry WC, Rohe DE, Keith RL. Quality of life
after surgical treatment of cancer of the larynx. Ann Otol Rhinol Laryn-
gol 1995;104:763–769.
Laryngoscope 122: May 2012 Sherman et al.: TALK Score for Larynx Preservation
1049
4. Lehmann W, Krebs H. Interdisciplinary rehabilitation of the laryngecto-
mee. Recent Results Cancer Res 1991;121:442–449.
5. Hassmann E, Skotnicka B. Feasibility of supracricoid laryngectomy based on
pathological examination. Eur Arch Otorhinolaryngol 1998;255:68–73.
6. Weinstein GS, El-Sawy MM, Ruiz C, et al. Laryngeal preservation with
supracricoid partial laryngectomy results in improved quality of life when
compared with total laryngectomy. Laryngoscope 2001;111:191–199.
7. Gilbert RW, Birt D, Shulman H, et al. Correlation of tumor volume with
local control in laryngeal carcinoma treated by radiotherapy. Ann Otol
Rhinol Laryngol 1987;96:514–518.
8. The Department of Veterans Affairs Laryngeal Cancer Study Group.
Induction chemotherapy plus radiation compared with surgery plus
radiation in patients with advanced laryngeal cancer. N Engl J Med
1991;324:1685–1690.
9. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sah-
moud T. Larynx preservation in pyriform sinus cancer: preliminary
results of a European Organization for Reasearch and Treatment of
Cancer phase III trial. J Natl Cancer Inst 1996;88:890–899.
10. Terrell JE, Fisher SG, Wolf GT. Long-term quality of life after treatment of
laryngeal cancer. Arch Otolaryngol Head Neck Surg 1998;124:964–971.
11. Pfister DG, Bajorin D, Motzer R, et al. Cisplatin, fluorouracil, and leucovo-
rin. Increased toxicity without improved response in squamous cell head
and neck cancer. Arch Otolaryngol Head Neck Surg 1994;120:89–95.
12. Maluf F, Sherman EJ, Kraus DH, et al. Long-term follow-up in patients
treated with a larynx preservation approach using sequential chemo-
therapy and radiation therapy: the Memorial Hospital experience. Acta
Oncologica Brasileira 2000;20:78–82.
13. Osman I, Sherman E, Singh B, et al. Alteration of p53 pathway in squa-
mous cell carcinoma of the head and neck: impact on treatment outcome
in patients treated with larynx preservation intent. J Clin Oncol 2002;
20:2980–2987.
14. Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH.
High dose cis-platinum diammine dichloride: amelioration of renal toxic-
ity by mannitol diuresis. Cancer 1977;39:1372–1381.
15. Vikram B, Strong E, Shah J, et al. A non-looping afterloading technique
for base of tongue implants: results in the first 20 patients. Int J Radiat
Oncol Biol Phys 1985;11:1853–1855.
16. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon: stage migra-
tion and new diagnostic technology techniques as a source for misleading
statistics for survival in cancer.NEngl J Med 1985;312:1604–1608.
17. Barbera L, Groome PA, Mackillop WJ, et al. The role of computed tomography
in the Tclassification of laryngeal carcinoma. Cancer 2001;91:394–407.
18. Mick R, Vokes EE, Weichselbaum RR, Panje WR. Prognostic factors in
advanced head and neck cancer patients undergoing multimodality ther-
apy. Otolaryngol Head Neck Surg 1991;105:62–73.
19. Piccirillo JF, Sasaki CT, Wells CK, Feinstein AR. New clinical severity
staging system for cancer of the larynx. Ann Otol Rhinol Laryngol 1994;
103:83–92.
20. Pugliano FA, Piccirillo JF, Zequeira MR, Fredrickson JM, Perez CA, Simp-
son JR. Symptoms as an index of biologic behavior in head and neck
cancer. Otolaryngol Head Neck Surg 1999;120:380–386.
21. Lassaletta L, Garcia-Pallares M, Morera E, Bernaldez R, Gavilan J. T3
glottic cancer: oncologic results and prognostic factors. Otolaryngol
Head Neck Surg 2001;124:556–560.
22. Franchin G, Minatel E, Gobitti C, et al. Radiation treatment of glottic
squamous cell carcinoma, stage I and II: analysis of factors affecting
prognosis. Int J Radiat Oncol Biol Phys 1998;40:541–548.
23. Singh B, Bhaya M, Zimbler M, et al. Impact of comorbidity on outcome of
young patients with head and neck squamous cell carcinoma. Head
Neck 1998;20:1–7.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classi-
fying prognostic comorbidity in longitudinal studies: development and
validation. J Chronic Dis 1987;40:373–383.
25. Cognetti F, Pinnaro P, Ruggeri EM, et al. Prognostic factors for chemother-
apy response and survival using combination chemotherapy as initial
treatment of advanced head and neck squamous cell cancer. J Clin
Oncol 1989;7:829–837.
26. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette
smoking and mutation of the p53 gene in squamous-cell carcinoma of
the head and neck. N Engl J Med 1995;332:712–717.
27. Temam S, Flahault A, Perie S, et al. p53 gene status as a predictor of tu-
mor response to induction chemotherapy of patients with locoregionally
advanced squamous cell carcinomas of the head and neck. J Clin Oncol
2000;18:385–394.
28. De Boer MF, Van den Borne B, Pruyn JF, et al. Psychosocial and physical
correlates of survival and recurrence in patients with head and neck carci-
noma: results of a 6-year longitudinal study. Cancer 1998;83:2567–2579.
29. Himberlin C, Merol JC, Nasca S, et al. Prognostic significance of routine
clinical and laboratory data in advanced head and neck cancers. Anti-
cancer Res 1996;16:1005–1010.
30. Huang GW, Nong HT, Yu QS, Kinjoh K, Nakamura M, Kosugi T. Platelet
aggregation in head and neck tumors in China. Laryngoscope 1997;107:
1142–1145.
31. Cheng SH, Jian JJ, Tsai SY, et al. Prognostic features and treatment out-
come in locoregionally advanced nasopharyngeal carcinoma following
concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol
Phys 1998;41:755–762.
32. Medow MA, Weed HG, Schuller DE. Simple predictors of survival in head
and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg
2002;128:1282–1286.
33. Wolf G, Hong W, Fisher S, et al. Larynx preservation with induction chem-
otherapy and radiation in advanced laryngeal cancer: final results of
the VA laryngeal cancer study group cooperative trial. Proc Amer Soc
Clin Oncol 1993;12:277.
34. Spaulding MB, Fischer SG, Wolf GT. Tumor response, toxicity, and sur-
vival after neoadjuvant organ-preserving chemotherapy for advanced la-
ryngeal carcinoma. The Department of Veterans Affairs Cooperative
Laryngeal Cancer Study Group. J Clin Oncol 1994;12:1592–1599.
35. Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat
Methodol 1972;34:187–220.
36. Zahalsky AJ, Sherman EJ, Kraus D, et al. A multivariate assessment of
concomitant boost (CB) radiation therapy (RT) and cisplatin versus con-
ventional RT as part of a larynx preservation (LP) strategy. Proc Am
Soc Clin Oncol 2001;20:(Abstract 898).
37. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the
yield of medical tests. JAMA 1982;247:2543–2546.
38. Begg CB, Cramer LD, Venkatraman ES, Rosai J. Comparing tumour stag-
ing and grading systems: a case study and a review of the issues, using
thymoma as a model. Stat Med 2000;19:1997–2014.
39. Schemper M, Smith TL. A note on quantifying follow-up in studies of fail-
ure time. Control Clin Trials 1996;17:343–346.
40. McNeil BJ, Weichselbaum R, Pauker SG. Speech and survival: tradeoffs
between quality and quantity of life in laryngeal cancer. N Engl J Med
1981;305:982–987.
41. DiNardo LJ, Kaylie DM, Isaacson J. Current treatment practices for early
laryngeal carcinoma. Otolaryngol Head Neck Surg 1999;120:30–37.
42. Bjordal K, Freng A, Thorvik J, Kaasa S. Patient self-reported and clini-
cian-rated quality of life in head and neck cancer patients: a cross-sec-
tional study. Eur J Cancer B Oral Oncol 1995;31B:235–241.
43. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: compar-
ing views of patients with cancer with those of doctors, nurses, and gen-
eral public. BMJ 1990;300:1458–1460.
44. Spitz M. Epidemiology and risk factors for head and neck cancer. Semin
Oncol 1994;21:281–288.
45. Saracci R. The interactions of tobacco smoking and other agents in cancer
etiology. Epidemiol Rev 1987;9:175–193.
46. Gillison ML, Koch WM, Shah KV. Human papillomavirus in head and
neck squamous cell carcinoma: are some head and neck cancers a sexu-
ally transmitted disease? Curr Opin Oncol 1999;11:191–199.
47. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal associa-
tion between human papillomavirus and a subset of head and neck can-
cers. J Natl Cancer Inst 2000;92:709–720.
48. Gillison ML, Lowy DR. A causal role for human papillomavirus in head
and neck cancer. Lancet 2004;363:1488–1489.
49. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with
human papillomavirus-positive head and neck squamous cell carcinoma
in a prospective clinical trial. J Natl Cancer Inst 2008;100:261–269.
50. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival
of patients with oropharyngeal cancer. N Engl J Med 2010;363:24–35.
51. Gillison ML, D’Souza G, Westra W, et al. Distinct risk factor profiles for
human papillomavirus type 16-positive and human papillomavirus
type 16-negative head and neck cancers. J Natl Cancer Inst 2008;100:
407–420.
52. Bradford CR, Zhu S, Wolf GT, et al. Overexpression of p53 predicts organ
preservation using induction chemotherapy and radiation in patients with
advanced laryngeal cancer. Department of Veterans Affairs Laryngeal Can-
cer Study Group. Otolaryngol Head Neck Surg 1995;113:408–412.
53. Gregg CM, Beals TE, McClatchy KM, Fisher SG, Wolf GT. DNA content
and tumor response to induction chemotherapy in patients with
advanced laryngeal squamous cell carcinoma. Otolaryngol Head Neck
Surg 1993;108:731–737.
54. Johnston PG, Mick R, Recant W, et al. Thymidylate synthase expression
and response to neoadjuvant chemotherapy in patients with advanced
head and neck cancer. J Natl Cancer Inst 1997;89:308–313.
55. Teknos TN, Cox C, Barrios MA, et al. Tumor angiogenesis as a predictive
marker for organ preservation in patients with advanced laryngeal car-
cinoma. Laryngoscope 2002;112:844–851.
56. Staton J, Robbins KT, Newman L, Samant S, Sebelik M, Vieira F. Factors
predictive of poor functional outcome after chemoradiation for advanced
laryngeal cancer. Otolaryngol Head Neck Surg 2002;127:43–47.
57. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabil-
ities of developing breast cancer for white females who are being exam-
ined annually. J Natl Cancer Inst 1989;81:1879–1886.
58. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of
the Gail et al. model of breast cancer risk prediction and implications
for chemoprevention. J Natl Cancer Inst 2001;93:358–366.
Laryngoscope 122: May 2012 Sherman et al.: TALK Score for Larynx Preservation
1050
